Contact Person
David Munis Zepernick

Head of Business Development and Public Affairs

Phone: (M) +45 2498 1668


Below you will find the latest news from MVA. You can also sign up to our newsletter MVA Update.

MVA Update is an electronic newsletter providing you with news about MVA and an overview of our events and other relevant events in Medicon Valley. You can also check out our calendar for more information about life science events in the region.

If you have any questions regarding our news section or media inquiries then please contact David Munis Zepernick, Head of Press on +45 2498 1668.

06 Aug

The European Fight Against The Covid-19 Coronavirus – get an overview of the situation in this recently published Labiotech article

What is the current situation (which changes on a daily basis)? How far are we from a vaccine? Which technologies are involved? Who are the key players? There are more questions than answers out there, but the recently published article

06 Jul

New business column about the Danish life science strategy by MVA chairman of the board, Søren Bregenholt and board member and General Manager of AbbVie Scandinavia, Linn Mandahl

Read the newly published MedWatch business column “Think bigger when revisiting the national Danish life science strategy” by Medicon Valley Alliance chairman Søren Bregenholt, CEO Macrophage Pharma and member of the Medicon Valley Alliance Board of Directors and General Manager

03 Jul

UNION Therapeutics will test candidate found to be 40 times as potent against COVID-19 as remdesivir.

In a press release issued Wednesday 1st of July, MVA-member company, UNION Therapeutics, announces that they have received approval from Danish Medicines Agency to initiate clinical study with niclosamide for treatment of COVID-19. Niclosamide has been identified as a potent inhibitor

29 Jun

SmiLe Incubator in Lund launches free online program targeting students and early stage entrepreneurs

Our Friends at SmiLe Incubator is now launching their e-Campus program. The program is aimed at young professionals and academics looking to start or to explore a business or career in the life science sector. SmiLe e-Campus stands out for

24 Jun

Interview with CEO, Nils Brünner, MVA-member, Scandion Oncology, about the recent partnership with MVA-member, Alligator Bioscience

When Medicon Valley Alliance Oncology Network was founded back in September 2016 by prof. Nils Brünner, University of Copenhagen, and prof. Carl Borrebaeck, CREATE Health, Lund University, the explicit ambition was to initiate an oncology network focusing on best practice,

22 Jun

MVA Oncology Network members partner up and receive a 800.000 EUR grant from Eurostars

Ole Thastrup, CEO, 2CureX MVA-member, 2cureX, and MVA-member, Scandion Oncology, have just announced a new partnership with Erasmus Medical Centre, Rotterdam and received a  grant of 800.000 EUR from Eurostars, which will be used to study if Scandion Oncology’s drug

10 Jun

Interview with Annelie Uvhagen, Director, Business Area Life Sciences, TECHNIA about doing business in the shadow of the COVID-19 crisis

In the recently distributed MVA Newsletter, we asked, Annelie Uvhagen, Director, Business Area Life Sciences, from MVA-member company, TECHNIA a few questions about doing business in the shadow of the COVID-19 crisis. Read the full interview below. Q1) TECHNIA is

10 Jun

Interview with CEO of MVA-member, Chart Biotech, Sancha Salgueiro, about vaccine development and the challenges involved in developing a COVID-19 vaccine

In our series of MVA-member company interviews, we have also reached out to MVA-member, Chart Biotech, and asked CEO, Sancha Salgueiro, a few specific questions about vaccine development and the challenges involved in developing a COVID-19 vaccine. Q1: What are

08 Jun

400 mio SEK investment from the Swedish Government in Almi Invest will benefit Medicon Valley too

In a recent press release, The Swedish Government has just announced a 400 mio SEK investment in the  venture capital company Almi Invest to help innovative start-ups cope with the economic consequences of the Covid-19 crisis. As life science is